DIA Biosimilars 2013

Millennium

Millenium expands on cancer treatment Velcade

Thursday, April 28, 2011 12:32 PM

Cambridge-based pharmaceutical company Millennium and their parent company Takeda Pharmaceutical, based in Japan, report they have submitted two supplemental new drug applications (NDAs) to the FDA for Velcade, a cancer treatment, according to Mass High Tech.

More... »

Cenduit: Now with Patient Reminders

Takeda, Amgen phase III motesanib trial fails

Friday, April 1, 2011 10:53 AM

Amgen, Takeda Pharmaceutical, and Millennium, a division of Takeda, announced unfavorable results from the MONET1 pivotal phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival.

More... »

CRF Health – eCOA Forum

Cytel names Jim Baker VP

Tuesday, March 22, 2011 12:00 PM

Cambridge, Mass.-based Cytel, a provider of clinical trial design and implementation services and software, has named Jim Baker vice president of clinical research services.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs